Bivalent recombinant protein vaccine (COVID-19)

· Sanofi Pasteur, a Sanofi Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bivalent recombinant protein vaccine (COVID-19), covering 2026-06-03 to 2026-06-03. Get the full timeline:

Most recent: Clinical Trial Results: Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older [Phase 3]

See pricing